Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valeriana officinalis, commonly known as valerian, is a perennial flowering plant whose root extract is widely used as an herbal supplement, particularly for the treatment of sleep disorders like insomnia. [17] It is recognized as GRAS (Generally Recognized as Safe) by the FDA in the United States and is marketed in various over-the-counter preparations. Beyond its traditional use as a sedative, preclinical research suggests Valeriana officinalis possesses anticonvulsant and anticancer properties. Its mechanism of action is thought to be multifactorial, involving modulation of the GABAergic system, where active compounds like valerenic acid may act as positive modulators of GABA-A receptors. [29, 37] Furthermore, studies have indicated that valerian and its components can inhibit histone deacetylase (HDAC) activity and alter DNA methylation, pointing to an epigenetic mechanism for its observed anti-proliferative effects against cancer cells, such as in breast cancer models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valeriana officinalis.